Pharmaceutical Business review

Newron acquires Hunter-Fleming

As announced earlier, shareholders of Hunter-Fleming now hold 3.1% in Newron.

Italy based Newron Pharmaceuticals is a biopharmaceutical company focused on novel therapies for diseases of the central nervous system and pain.